Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22019700 | 0.83 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPTHPGDKDM4E | |
| SCHEMBL22693486 | 0.80 | KDM4E (0.35) | ALDH1A1LMNAMAPTHPGDKDM4E | |
| SCHEMBL10211697 | 0.80 | ACHE (0.31) | GABRA1GABRB2 | |
| SCHEMBL20445177 | 0.73 | — | — | |
| SCHEMBL19355716 | 0.72 | ALDH1A1 (0.31) | ALDH1A1LMNAHPGDSMN1; SMN2GAA | |
| SCHEMBL22856786 | 0.70 | — | — | |
| SCHEMBL786450 | 0.69 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTHPGDKDM4E | |
| SCHEMBL9967707 | 0.69 | — | — | |
| SCHEMBL9918172 | 0.69 | — | — | |
| SCHEMBL10153919 | 0.69 | DAO (0.38) | ALDH1A1HPGDPOLBGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| WO-2020102098-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-23 | — | — | US | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100048555-A1 | IMIDAZOTHIAZOLE DERIVATIVES AS MARK INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | ALDH1A1 3021/4885LMNA 1432/4885MAPT 147/4885 |
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885LMNA 3118/4885MAPT 2833/4885 |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | ALDH1A1 4808/4885LMNA 3141/4885MAPT 4303/4885 |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRM5, GRIK5, GRM1 | ALDH1A1 414/4885LMNA 4522/4885MAPT 1283/4885 |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | ALDH1A1 670/4885LMNA 2040/4885MAPT 2521/4885 |
| US-20170334887-A1 | Imidazole-Based Antimicrobial Agents | TLR5, NISCH, SLC11A2 | ALDH1A1 1629/4885LMNA 4548/4885MAPT 1161/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | ALDH1A1 1486/4885LMNA 4231/4885MAPT 709/4885 |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | ALDH1A1 2777/4885LMNA 627/4885MAPT 707/4885 |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | ALDH1A1 2781/4885LMNA 1725/4885MAPT 195/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | ALDH1A1 3021/4885LMNA 1432/4885MAPT 147/4885 |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885LMNA 1699/4885MAPT 2020/4885 |
| US-20100048555-A1 | IMIDAZOTHIAZOLE DERIVATIVES AS MARK INHIBITORS | MAPT, MARK1, MARK4 | ALDH1A1 2739/4885LMNA 2088/4885MAPT 1/4885 |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD79B, CLTB, FCGR3B | ALDH1A1 1486/4885LMNA 4231/4885MAPT 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.